Blog

GLP-1s and Cancer Risk: What the Latest Research Shows

New studies suggest GLP-1 drugs may reduce cancer risk in 6 out of 7 cancers studied. Here's what the research actually says.

Here’s something that caught our attention this week. NPR reported on mounting evidence that GLP-1 drugs - the same compounds generating massive interest for weight loss and diabetes management - may also help reduce cancer risk.

The story, based on research presented at the American Society of Clinical Oncology (ASCO) meeting, is genuinely interesting. But it comes with some important caveats that are worth understanding.

The Headline Numbers

The most prominent study tracked medical and prescription records of over 10,000 patients with early-stage cancer. The researchers found that GLP-1s were associated with reduced cancer risk in six out of seven cancers studied, with four of those reductions reaching statistical significance.

The specific findings:

  • Breast cancer - statistically significant risk reduction
  • Liver cancer - statistically significant risk reduction
  • Colorectal cancer - statistically significant risk reduction
  • Non-small cell lung cancer - statistically significant risk reduction
  • Kidney cancer - some reduction, not statistically significant
  • Prostate cancer - some reduction, not statistically significant
  • Pancreatic cancer - least affected

The non-small cell lung cancer numbers are particularly striking. Among patients not on a GLP-1, 22.3% experienced progression to Stage IV disease. Among those taking GLP-1s, that figure was just 10%.

Beyond Weight Loss

What makes this research particularly interesting is that the cancer risk reductions appeared across cancers with and without known connections to obesity. If GLP-1s were only reducing cancer risk through weight loss, you’d expect to see the strongest effects in obesity-linked cancers like breast and colorectal. But the lung cancer data suggests something else may be happening.

GLP-1 drugs act on hormonal pathways in the brain and gut. They reduce hunger, slow digestion, and alter metabolic signalling. Researchers are now investigating whether these compounds also have anti-inflammatory effects that could help suppress tumour growth independently of their weight loss properties.

As NPR reported, GLP-1s were originally developed as diabetes treatments, but because they act on powerful metabolic levers, they’ve since proven useful against obesity, heart disease, sleep apnea, and potentially addiction. The cancer data adds another dimension to an already complex picture.

The Important Caveats

Before anyone gets too excited, the experts quoted in the NPR piece are appropriately cautious.

Dr. Julie Gralow, chief medical officer of ASCO, pointed out that these analyses used retrospective medical databases. They didn’t account for relevant nuances like a patient’s comorbidities, exercise habits, or dietary patterns. People who are prescribed GLP-1s may also be more engaged with their healthcare generally, which could confound the results.

That said, Gralow noted the data is “consistent with what is known about how obesity is a driver for about a dozen cancers, and how healthy living is significant in both illness and recovery.”

Another study presented at the conference specifically examined breast cancer risk reduction, adding to the evidence base. Researchers at the Rutgers Cancer Institute are among those now designing prospective trials to try to separate the weight-loss effect from any direct anti-cancer properties.

What the Research Says

The current evidence is correlative, not causal. That’s an important distinction. The studies show an association between GLP-1 use and reduced cancer risk, but they can’t prove the drugs are directly responsible.

However, the biological plausibility is there. Chronic inflammation is a known driver of cancer development, and GLP-1s have demonstrated anti-inflammatory properties in multiple studies. The question is whether those anti-inflammatory effects are strong enough to meaningfully influence cancer outcomes.

The research community is now working to answer that question with more rigorous study designs. Several clinical trials are being planned or underway that will look specifically at GLP-1s in cancer prevention and treatment contexts.

Why This Matters for the Research Community

For those of us following peptide research, the cancer angle adds another layer to the GLP-1 story. These compounds were already interesting for their metabolic effects. The possibility that they could also influence cancer risk - even modestly - makes them even more significant from a research perspective.

It’s worth noting that this is early-stage research. The studies presented at ASCO are the beginning of a research conversation, not the conclusion. We’ll be watching closely as prospective trials deliver more definitive data.

In the meantime, if you’re interested in the mechanisms behind GLP-1 compounds, our peptide research guides cover the basics of how these receptor agonists work.

Sources

Interested in discussing the latest peptide research? The Grey Highway Telegram community is where the conversation happens.

Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.